Pearl Therapeutics, an AstraZeneca group company, is developing unique dual and triple combination products for the treatment of widely prevalent respiratory diseases, including chronic obstructive pulmonary disease. Pearl's current focus is on making advanced inhaled therapies available to broad patient populations via familiar and accepted metered dose inhalers.

Latest News

March 18, 2015

AstraZeneca announces positive Phase III...

July 1, 2013

AstraZeneca Completes Acquisition of Pearl...

June 9, 2013

Pearl Therapeutics to be Acquired by...

More Press Releases